Advances in photodynamic therapy for the treatment of hilar biliary tract cancer

Future Oncology

Volumn 6, Issue 12, 2010, Pages 1925-1936

  Kiesslich, Tobias ^a   Neureiter, Daniel ^a   Wolkersdrfer, Gernot W ^a   Plaetzer, Kristjan ^b   Berr, Frieder ^a  

^a PARACELSUS MEDICAL UNIVERSITY   (Austria)

^b UNIVERSITY OF SALZBURG   (Austria)

Author keywords

biliary tract cancer; Foscan ; photodynamic therapy; Photofrin

Indexed keywords

HEMATOPORPHYRIN DERIVATIVE; MONO LEVO ASPARTYL CHLORINE; PHOTOFRIN; PHOTOSAN; TEMOPORFIN; TETRAKIS PYRIDYL TETRAHYDROPORPHYRIN; UNCLASSIFIED DRUG;

BARE METAL STENT; BILIARY TRACT CANCER; BILIARY TRACT DRAINAGE; CANCER INHIBITION; CANCER STAGING; CANCER SURVIVAL; CHOLANGITIS; CHOLESTASIS; CLINICAL EFFECTIVENESS; EMPYEMA; LIVER FAILURE; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME;

ANIMALS; ANTINEOPLASTIC PROTOCOLS; BILIARY TRACT NEOPLASMS; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; DRUG EVALUATION, PRECLINICAL; HUMANS; MOLECULAR TARGETED THERAPY; PALLIATIVE CARE; PHOTOCHEMOTHERAPY;

EID: 78650465341     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.10.147     Document Type: Review

References (74)

1. Blechacz B, Gores GJ: Cholangiocarcinoma: advances in pathogenesis, diagnosis, and treatment. Hepatology 48(1), 308-321 (2008).
2. Shaib Y, El-Serag HB: The epidemiology of cholangiocarcinoma. Semin. Liver Dis. 24(2), 115-125 (2004).
3. Kiesslich T, Wolkersdorfer G, Neureiter D, Salmhofer H, Berr F: Photodynamic therapy for non-resectable perihilar cholangiocarcinoma. Photochem. Photobiol. Sci. 8(1), 23-30 (2009).
4. Aljiffry M, Walsh MJ, Molinari M: Advances in diagnosis, treatment and palliation of cholangiocarcinoma: 1990-2009. World J. Gastroenterol. 15(34), 4240-4262 (2009).
5. Khan SA, Toledano MB, Taylor-Robinson SD: Epidemiology, risk factors, and pathogenesis of cholangiocarcinoma. HPB (Oxford) 10(2), 77-82 (2008).
6. Lazaridis KN, Gores GJ: Cholangiocarcinoma. Gastroenterology 128(6), 1655-1667 (2005).
7. Witzigmann H, Wiedmann M, Wittekind C, Mossner J, Hauss J: Therapeutical concepts and results for Klatskin tumors. Dtsch Arztebl. Int. 105(9), 156-161 (2008).
8. Verslype C, Prenen H, Van Cutsem E: The role of chemotherapy in biliary tract carcinoma. HPB (Oxford) 10(3), 164-167 (2008).
9. Valle J, Wasan H, Palmer DH et al.: Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N. Engl. J. Med. 362(14), 1273-1281 (2010).
10. Kahaleh M, Mishra R, Shami VM et al.: Unresectable cholangiocarcinoma: comparison of survival in biliary stenting alone versus stenting with photodynamic therapy. Clin. Gastroenterol. Hepatol. 6(3), 290-297 (2008).
11. Ortner MA, Liebetruth J, Schreiber S et al.: Photodynamic therapy of nonresectable cholangiocarcinoma. Gastroenterology 114(3), 536-542 (1998)
12. Ortner ME, Caca K, Berr F et al.: Successful photodynamic therapy for nonresectable cholangiocarcinoma: a randomized prospective study. Gastroenterology 125(5), 1355-1363 (2003).
13. Gao F, Bai Y, Ma SR, Liu F, Li ZS: Systematic review: photodynamic therapy for unresectable cholangiocarcinoma. J. Hepatobiliary Pancreat. Sci. 17(2), 125-131 (2010).
14. Chahal P, Baron TH: Endoscopic palliation of cholangiocarcinoma. Curr. Opin. Gastroenterol. 22(5), 551-560 (2006).
15. McCaughan JS, Jr., Mertens BF, Cho C, Barabash RD, Payton HW: Photodynamic therapy to treat tumors of the extrahepatic biliary ducts. A case report. Arch. Surg. 126(1), 111-113 (1991).
16. Allison RR, Zervos E, Sibata CH: Cholangiocarcinoma: an emerging indication for photodynamic therapy. Photodiagnosis Photodyn. Ther. 6(2), 84-92 (2009).
17. Ortner MA: Photodynamic therapy for cholangiocarcinoma: overview and new developments. Curr. Opin. Gastroenterol. 25(5), 472-476 (2009).
18. van Duijnhoven FH, Aalbers RI, Rovers JP, Terpstra OT, Kuppen PJ: The immunological consequences of photodynamic treatment of cancer, a literature review. Immunobiology 207(2), 105-113 (2003).
19. Plaetzer K, Kiesslich T, Oberdanner CB, Krammer B: Apoptosis following photodynamic tumor therapy: induction, mechanisms and detection. Curr. Pharm. Des. 11(9), 1151-1165 (2005).
20. Plaetzer K, Krammer B, Berlanda J, Berr F, Kiesslich T: Photophysics and photochemistry of photodynamic therapy: fundamental aspects. Lasers Med. Sci. 24(2), 259-268 (2009).
21. Robertson CA, Evans DH, Abrahamse H: Photodynamic therapy (PDT): a short review on cellular mechanisms and cancer research applications for PDT. J. Photochem. Photobiol. B 96(1), 1-8 (2009).
22. Dolmans DE, Fukumura D, Jain RK: Photodynamic therapy for cancer. Nat. Rev. Cancer 3(5), 380-387 (2003).
23. Triesscheijn M, Baas P, Schellens JH, Stewart FA: Photodynamic therapy in oncology. Oncologist 11(9), 1034-1044 (2006).
24. Allison RR, Downie GH, Cuenca R, Hu X-H, Childs CJ, Sibata CH: Photosensitizers in clinical PDT. Photodiagnosis Photodyn. Ther. 1(1), 27-42 (2004).
25. Berlanda J, Kiesslich T, Engelhardt V, Krammer B, Plaetzer K: Comparative in vitro study on the characteristics of different photosensitizers employed in PDT. J. Photochem. Photobiol. B 100(3), 173-180 (2010).
26. Cheon YK, Cho YD, Moon JH et al.: Diagnostic utility of interleukin-6 (IL-6) for primary bile duct cancer and changes in serum IL-6 levels following photodynamic therapy. Am. J. Gastroenterol. 102(10), 2164-2170 (2007).
27. Berr F, Wiedmann M, Tannapfel A et al.: Photodynamic therapy for advanced bile duct cancer: evidence for improved palliation and extended survival. Hepatology 31(2), 291-298 (2000).
28. Wolkersdoerfer G, Emmanuel K, Denzer U et al.: Temoporfin improves tumoricidal efficacy of photodynamic therapy (PDT) for bile duct cancer. Abstract at the 33rd congress of the European Society for Medical Oncology, Stockholm, Sweden. Ann. Oncol. 19(Suppl. 8), 176 (2008).
29. Berr F: Photodynamic therapy for cholangiocarcinoma. Semin. Liver Dis. 24(2), 177-187 (2004).
30. Ortner MA: Photodynamic therapy in cholangiocarcinomas. Best Pract. Res. Clin. Gastroenterol. 18(1), 147-154 (2004).
31. Fuks D, Bartoli E, Delcenserie R et al.: Biliary drainage, photodynamic therapy and chemotherapy for unresectable cholangiocarcinoma with jaundice. J. Gastroenterol. Hepatol. 24(11), 1745-1752 (2009).
32. Van Beers BE: Diagnosis of cholangiocarcinoma. HPB (Oxford) 10(2), 87-93 (2008).
33. Cao LQ, Xue P, Lu HW, Zheng Q, Wen ZL, Shao ZJ: Hematoporphyrin derivative-mediated photodynamic therapy inhibits tumor growth in human cholangiocarcinoma in vitro and in vivo. Hepatol. Res. 39(12), 1190-1197 (2009).
34. Wang JB, Liu LX, Pan SH, Wang CY, Fu QF: Therapeutic effect of photodynamic therapy using hematoporphyrin monomethyl ether (HMME) on human cholangiocarcinoma cell line QBC939. Neoplasma 57(1), 79-85 (2010).
35. Wong Kee Song LM, Wang KK, Zinsmeister AR: Mono-l-aspartyl chlorin e6 (Npe6) and hematoporphyrin derivative (HPD) in photodynamic therapy administered to a human cholangiocarcinoma model. Cancer 82(2), 421-427 (1998).
36. Kasuya K, Shimazu M, Suzuki M et al.: Novel photodynamic therapy against biliary tract carcinoma using mono-l-aspartyl chlorine e6: basic evaluation for its feasibility and efficacy. J. Hepatobiliary Pancreat. Sci. 17(3), 313-321 (2010).
37. Kiesslich T, Berlanda J, Plaetzer K, Krammer B, Berr F: Comparative characterization of the efficiency and cellular pharmacokinetics of Foscan-and Foslip-based photodynamic treatment in human biliary tract cancer cell lines. Photochem. Photobiol. Sci. 6(6), 619-627 (2007).
38. Kiesslich T, Neureiter D, Alinger B et al.: Uptake and phototoxicity of meso-tetrahydroxyphenyl chlorine are highly variable in human biliary tract cancer cell lines and correlate with markers of differentiation and proliferation. Photochem. Photobiol. Sci. 9(5), 734-743 (2010).
39. Samkoe KS, Chen A, Rizvi I et al.: Imaging tumor variation in response to photodynamic therapy in pancreatic cancer xenograft models. Int. J. Radiat. Oncol. Biol. Phys. 76(1), 251-259 (2010).
40. Pereira SP, Ayaru L, Rogowska A, Mosse A, Hatfield AR, Bown SG: Photodynamic therapy of malignant biliary strictures using meso- tetrahydroxyphenylchlorin. Eur. J. Gastroenterol. Hepatol. 19(6), 479-485 (2007).
41. Oertel M, Schastak SI, Tannapfel A et al.: Novel bacteriochlorine for high tissue-penetration: photodynamic properties in human biliary tract cancer cells in vitro and in a mouse tumour model. J. Photochem. Photobiol. B. 71(1-3), 1-10 (2003).
42. Berr F, Tannapfel A, Lamesch P et al.: Neoadjuvant photodynamic therapy before curative resection of proximal bile duct carcinoma. J. Hepatol. 32(2), 352-357 (2000).
43. Zoepf T, Jakobs R, Arnold JC, Apel D, Riemann JF: Palliation of nonresectable bile duct cancer: improved survival after photodynamic therapy. Am. J. Gastroenterol. 100(11), 2426-2430 (2005).
44. Witzigmann H, Berr F, Ringel U et al.: Surgical and palliative management and outcome in 184 patients with hilar cholangiocarcinoma: palliative photodynamic therapy plus stenting is comparable to R1/R2 resection. Ann. Surg. 244(2), 230-239 (2006).
45. Matull WR, Dhar DK, Ayaru L et al.: R0 but not R1/R2 resection is associated with better survival than palliative photodynamic therapy in biliary tract cancer. Liver Int. DOI: 10.1111/ j.1478-3231.2010.02345.x (2010) (Epub ahead of print).
46. Baisden JM, Kahaleh M, Weiss GR et al.: Multimodality treatment with helical tomotherapy intensity modulated radiotherapy, capecitabine, and photodynamic therapy is feasible and well tolerated in patients with hilar cholangiocarcinoma. Gastrointest. Cancer Res. 2(5), 219-224 (2008).
47. Quyn AJ, Ziyaie D, Polignano FM, Tait IS: Photodynamic therapy is associated with an improvement in survival in patients with irresectable hilar cholangiocarcinoma. HPB (Oxford) 11(7), 570-577 (2009).
48. Gerhardt T, Rings D, Hoblinger A, Heller J, Sauerbruch T, Schepke M: Combination of bilateral metal stenting and trans-stent photodynamic therapy for palliative treatment of hilar cholangiocarcinoma. Z. Gastroenterol. 48(1), 28-32 (2010).
49. Wang LW, Li LB, Li ZS, Chen YK, Hetzel FW, Huang Z: Self-expandable metal stents and trans-stent light delivery: are metal stents and photodynamic therapy compatible? Lasers Surg. Med. 40(9), 651-659 (2008).
50. Svaasand LO: Optical dosimetry for direct and interstitial photoradiation therapy of malignant tumors. Prog. Clin. Biol. Res. 170, 91-114 (1984).
51. Wilson BC, Jeeves WP, Lowe DM: In vivo and post mortem measurements of the attenuation spectra of light in mammalian tissues. Photochem. Photobiol. 42(2), 153-162 (1985).
52. Sugawara H, Yasoshima M, Katayanagi K et al.: Relationship between interleukin-6 and proliferation and differentiation in cholangiocarcinoma. Histopathology 33(2), 145-153 (1998).
53. Okada K, Shimizu Y, Nambu S, Higuchi K, Watanabe A: Interleukin-6 functions as an autocrine growth factor in a cholangiocarcinoma cell line. J. Gastroenterol. Hepatol. 9(5), 462-467 (1994).
54. Shim CS, Cheon YK, Cha SW et al.: Prospective study of the effectiveness of percutaneous transhepatic photodynamic therapy for advanced bile duct cancer and the role of intraductal ultrasonography in response assessment. Endoscopy 37(5), 425-433 (2005).
55. Bown SG, Rogowska AZ, Whitelaw DE et al.: Photodynamic therapy for cancer of the pancreas. Gut 50(4), 549-557 (2002).
56. Wolkersdorfer GW, Emmanuel K, Denzer U et al.: Efficacy of temoporfin photodynamic therapy (PDT) for bile duct cancer. Abstract the 65th congress of the Deutschen Gesellschaft fr Verdauungs-und Stoffwechselkrankheiten (DGVS), Stuttgart, Germany. Z. Gastroenterol. 48, P371 (2010).
57. Wiedmann M, Caca K, Berr F et al.: Neoadjuvant photodynamic therapy as a new approach to treating hilar cholangiocarcinoma: a Phase II pilot study. Cancer 97(11), 2783-2790 (2003).
58. Baron TH: Photodynamic therapy: standard of care for palliation of cholangiocarcinoma? Clin. Gastroenterol. Hepatol. 6(3), 266-267 (2008).
59. Bridgewater J: Photodynamic therapy for biliary tract cancer. Br. J. Surg. 96(3), 225-226 (2009).
60. Saito H, Takada T, Miyazaki M et al.: Radiation therapy and photodynamic therapy for biliary tract and ampullary carcinomas. J. Hepatobiliary Pancreat. Surg. 15(1), 63-68 (2008). (Pubitemid 351279842)
61. Mazor O, Brandis A, Plaks V et al.: WST11, a novel water-soluble bacteriochlorophyll derivative; cellular uptake, pharmacokinetics, biodistribution and vascular-targeted photodynamic activity using melanoma tumors as a model. Photochem. Photobiol. 81(2), 342-351 (2005).
62. Brandis A, Mazor O, Neumark E, Rosenbach-Belkin V, Salomon Y, Scherz A: Novel water-soluble bacteriochlorophyll derivatives for vascular-targeted photodynamic therapy: synthesis, solubility, phototoxicity and the effect of serum proteins. Photochem. Photobiol. 81(4), 983-993 (2005).
63. Dumoulin FL, Gerhardt T, Fuchs S et al.: Phase II study of photodynamic therapy and metal stent as palliative treatment for nonresectable hilar cholangiocarcinoma. Gastrointest. Endosc. 57(7), 860-867 (2003).
64. Harewood GC, Baron TH, Rumalla A et al.: Pilot study to assess patient outcomes following endoscopic application of photodynamic therapy for advanced cholangiocarcinoma. J. Gastroenterol. Hepatol. 20(3), 415-420 (2005).
65. Wiedmann M, Berr F, Schiefke I et al.: Photodynamic therapy in patients with non-resectable hilar cholangiocarcinoma: 5 year follow-up of a prospective Phase II study. Gastrointest. Endosc. 60(1), 68-75 (2004).
66. Ayaru L, Bown SG, Pereira SP: Photodynamic therapy for pancreatic and biliary tract carcinoma. Int. J. Gastrointest. Cancer 35(1), 1-13 (2005).
67. Gerdes H; Memorial Sloan-Kettering Cancer Center, New York, NY, USA: Photodynamic therapy in treating patients with cancer of the bile duct, gallbladder or pancreas http://clinicaltrials.gov/ct2/show/ NCT00003923 (Accessed September 2010)
68. Berr F, Lohse A; Department of Internal Medicine I, Paracelsus Medical University, Salzburg, Austria: Single-arm study of photodynamic laser therapy using Foscan for non-curatively-resectable bile duct carcinoma http://clinicaltrials.gov/ct2/show/NCT0101 6002?term=NCT01016002&rank=1 (Accessed September 2010)
69. Ebert M., Schmid RM; Technical University of Munich at the Klinikum Rechts der Isar II. Medizinische Klinik, Munich, Germany: Gemcitabine- oxaliplatin and photodynamic therapy in cholangiocarcinoma (GemOx-PDT) http://clinicaltrials.gov/ct2/show/NCT0071 3687?term=NCT00713687&rank=1 (Accessed September 2010)
70. Ben Soussan E; Clinique de lAlma, Paris, France: Study using WST11 in patients with nonresectable or inoperable cholangiocarcinoma http://clinicaltrials.gov/ct2/show/NCT00975 039?term=NCT00975039&rank=1 (Accessed September 2010)
71. Pereira SP; University College London Hospitals, London, UK: Biliary stenting with or without photodynamic therapy in treating patients with locally advanced, recurrent, or metastatic cholangiocarcinoma or other biliary tract tumors that cannot be removed by surgery http://clinicaltrials.gov/ct2/show/ NCT00513 539?term=NCT00513539&rank=1 (Accessed September 2010)
72. Boyer J; University Hospital, Angers, France: Efficiency evaluation of photodynamic therapy with Photofrin® on unresectable type III or IV cholangiocarcinomas (CK/PDT) http://clinicaltrials.gov/ct2/show/NCT00540 735?term=NCT00540735&rank=1 (Accessed September 2010)
73. Kahaleh M; University of Virginia, Charlotteville, VA, USA: Photodynamic therapy (PDT) trial for palliation of cholangiocarcinoma http://clinicaltrials. gov/ct2/show/NCT00907 413?term=NCT00907413&rank=1 (Accessed September 2010)
74. Park DH, Asan Medical Center, Seoul South Korea: S1 and photodynamic therapy in cholangiocarcinoma http://clinicaltrials.gov/ct2/show/NCT0086 9635?term=NCT00869635&rank=1 (Accessed September 2010)